Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging.

Autry AW, Hashizume R, James CD, Larson PEZ, Vigneron DB, Park I.

Contrast Media Mol Imaging. 2018 Jul 30;2018:3215658. doi: 10.1155/2018/3215658. eCollection 2018.

2.

Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.

Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M.

J Neurooncol. 2018 Aug 27. doi: 10.1007/s11060-018-2977-3. [Epub ahead of print]

PMID:
30151703
3.

An overview of meningiomas.

Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV.

Future Oncol. 2018 Sep;14(21):2161-2177. doi: 10.2217/fon-2018-0006. Epub 2018 Aug 7. Review.

PMID:
30084265
4.

Computing with Spikes: The Advantage of Fine-Grained Timing.

Verzi SJ, Rothganger F, Parekh OD, Quach TT, Miner NE, Vineyard CM, James CD, Aimone JB.

Neural Comput. 2018 Jul 18:1-31. doi: 10.1162/neco_a_01113. [Epub ahead of print]

PMID:
30021083
5.

Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.

Pangeni RP, Zhang Z, Alvarez AA, Wan X, Sastry N, Lu S, Shi T, Huang T, Lei CX, James CD, Kessler JA, Brennan CW, Nakano I, Lu X, Hu B, Zhang W, Cheng SY.

Epigenetics. 2018;13(4):432-448. doi: 10.1080/15592294.2018.1469892. Epub 2018 Aug 6.

PMID:
29927689
6.

Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.

Linninger A, Hartung GA, Liu BP, Mirkov S, Tangen K, Lukas RV, Unruh D, James CD, Sarkaria JN, Horbinski C.

Neuro Oncol. 2018 Apr 5. doi: 10.1093/neuonc/noy051. [Epub ahead of print]

PMID:
29660019
7.

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, Gong W, Liu Y, Jiang B, Tang T, Patel R, Platanias LC, James CD, Stupp R, Lukas RV, Binder DC, Wainwright DA.

Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. doi: 10.1158/1078-0432.CCR-17-3573. Epub 2018 Mar 2.

PMID:
29500275
8.

MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma.

Huang T, Kim CK, Alvarez AA, Pangeni RP, Wan X, Song X, Shi T, Yang Y, Sastry N, Horbinski CM, Lu S, Stupp R, Kessler JA, Nishikawa R, Nakano I, Sulman EP, Lu X, James CD, Yin XM, Hu B, Cheng SY.

Cancer Cell. 2017 Dec 11;32(6):840-855.e8. doi: 10.1016/j.ccell.2017.11.005.

9.

An oral keratinocyte life cycle model identifies novel host genome regulation by human papillomavirus 16 relevant to HPV positive head and neck cancer.

Evans MR, James CD, Loughran O, Nulton TJ, Wang X, Bristol ML, Windle B, Morgan IM.

Oncotarget. 2017 Jun 1;8(47):81892-81909. doi: 10.18632/oncotarget.18328. eCollection 2017 Oct 10.

10.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC.

Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.

11.

Scaling up family planning in Sierra Leone: A prospective cost-benefit analysis.

Keen S, Begum H, Friedman HS, James CD.

Womens Health (Lond). 2017 Dec;13(3):43-57. doi: 10.1177/1745505717724617. Epub 2017 Aug 29.

PMID:
28849728
12.

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA.

Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. doi: 10.1158/1078-0432.CCR-17-0120. Epub 2017 Jul 27.

PMID:
28751450
13.

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.

Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP.

Transl Oncol. 2017 Aug;10(4):669-678. doi: 10.1016/j.tranon.2017.06.003. Epub 2017 Jun 30.

14.

Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP, Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski C, Stegh AH.

Cell Rep. 2017 May 30;19(9):1858-1873. doi: 10.1016/j.celrep.2017.05.014.

15.

Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing.

Hill VK, Kim JS, James CD, Waldman T.

PLoS One. 2017 May 2;12(5):e0176683. doi: 10.1371/journal.pone.0176683. eCollection 2017.

16.

Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.

Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM.

Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.

17.

Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.

Sita TL, Kouri FM, Hurley LA, Merkel TJ, Chalastanis A, May JL, Ghelfi ST, Cole LE, Cayton TC, Barnaby SN, Sprangers AJ, Savalia N, James CD, Lee A, Mirkin CA, Stegh AH.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4129-4134. doi: 10.1073/pnas.1702736114. Epub 2017 Apr 3.

18.

A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.

Zhou J, Tien AC, Alberta JA, Ficarro SB, Griveau A, Sun Y, Deshpande JS, Card JD, Morgan-Smith M, Michowski W, Hashizume R, James CD, Ligon KL, Snider WD, Sicinski P, Marto JA, Rowitch DH, Stiles CD.

Cell Rep. 2017 Mar 28;18(13):3167-3177. doi: 10.1016/j.celrep.2017.03.003.

19.

Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.

Wainwright DA, Horbinski CM, Hashizume R, James CD.

Neurotherapeutics. 2017 Apr;14(2):385-392. doi: 10.1007/s13311-017-0523-1. Review.

20.

Therapeutic Potential for Bone Morphogenetic Protein 4 in Human Malignant Glioma.

Xi G, Best B, Mania-Farnell B, James CD, Tomita T.

Neoplasia. 2017 Apr;19(4):261-270. doi: 10.1016/j.neo.2017.01.006. Epub 2017 Mar 7. Review.

21.

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM, Kelleher NL, James CD, Shilatifard A.

Nat Med. 2017 Apr;23(4):493-500. doi: 10.1038/nm.4296. Epub 2017 Feb 27.

22.

Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy.

Xi G, Li YD, Grahovac G, Rajaram V, Wadhwani N, Pundy T, Mania-Farnell B, James CD, Tomita T.

Mol Cancer. 2017 Jan 31;16(1):21. doi: 10.1186/s12943-017-0593-z.

23.

Li-Ion Synaptic Transistor for Low Power Analog Computing.

Fuller EJ, Gabaly FE, Léonard F, Agarwal S, Plimpton SJ, Jacobs-Gedrim RB, James CD, Marinella MJ, Talin AA.

Adv Mater. 2017 Jan;29(4). doi: 10.1002/adma.201604310. Epub 2016 Nov 22.

PMID:
27874238
24.

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.

Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T.

J Neurooncol. 2017 Feb;131(3):495-505. doi: 10.1007/s11060-016-2333-4. Epub 2016 Nov 15.

25.

The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine.

Lenzen A, Zhai L, Lauing KL, Gritsina G, Ladomersky E, Genet M, James CD, Bloch O, Wainwright DA.

Immunotherapy (Los Angel). 2016 Sep;2(3). pii: 125. Epub 2016 Sep 9.

26.

BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.

Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA.

Clin Cancer Res. 2016 Nov 1;22(21):5312-5321. Epub 2016 May 23.

27.

Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model.

Lee G, Auffinger B, Guo D, Hasan T, Deheeger M, Tobias AL, Kim JY, Atashi F, Zhang L, Lesniak MS, James CD, Ahmed AU.

Mol Cancer Ther. 2016 Dec;15(12):3064-3076. Epub 2016 Oct 7. Erratum in: Mol Cancer Ther. 2017 Jun;16(6):1199.

28.

A Combinatorial Model for Dentate Gyrus Sparse Coding.

Severa W, Parekh O, James CD, Aimone JB.

Neural Comput. 2017 Jan;29(1):94-117. doi: 10.1162/NECO_a_00905. Epub 2016 Oct 20.

PMID:
27764589
29.

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.

Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK.

Oncotarget. 2016 Nov 15;7(46):75839-75853. doi: 10.18632/oncotarget.12419.

30.

A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways.

Huang T, Alvarez AA, Pangeni RP, Horbinski CM, Lu S, Kim SH, James CD, J Raizer J, A Kessler J, Brenann CW, Sulman EP, Finocchiaro G, Tan M, Nishikawa R, Lu X, Nakano I, Hu B, Cheng SY.

Nat Commun. 2016 Oct 4;7:12885. doi: 10.1038/ncomms12885.

31.

Improving vaccine efficacy against malignant glioma.

Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing KL, Lulla RR, Fangusaro J, Lenzen A, Kumthekar P, Raizer JJ, Binder DC, James CD, Wainwright DA.

Oncoimmunology. 2016 Jun 10;5(8):e1196311. doi: 10.1080/2162402X.2016.1196311. eCollection 2016 Aug. Review.

32.

Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.

Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T.

Oncotarget. 2017 Jan 3;8(1):583-595. doi: 10.18632/oncotarget.11882.

33.

Advanced age negatively impacts survival in an experimental brain tumor model.

Ladomersky E, Zhai L, Gritsina G, Genet M, Lauing KL, Wu M, James CD, Wainwright DA.

Neurosci Lett. 2016 Sep 6;630:203-208. doi: 10.1016/j.neulet.2016.08.002. Epub 2016 Aug 1.

34.

Anion Effects in Oxidative Aliphatic Carbon-Carbon Bond Cleavage Reactions of Cu(II) Chlorodiketonate Complexes.

Saraf SL, Miłaczewska A, Borowski T, James CD, Tierney DL, Popova M, Arif AM, Berreau LM.

Inorg Chem. 2016 Jul 18;55(14):6916-28. doi: 10.1021/acs.inorgchem.6b00456. Epub 2016 Jul 5.

PMID:
27377103
35.

Single objective light-sheet microscopy for high-speed whole-cell 3D super-resolution.

Meddens MB, Liu S, Finnegan PS, Edwards TL, James CD, Lidke KA.

Biomed Opt Express. 2016 May 17;7(6):2219-36. doi: 10.1364/BOE.7.002219. eCollection 2016 Jun 1.

36.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.

Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1.

37.

MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.

Bell JB, Eckerdt FD, Alley K, Magnusson LP, Hussain H, Bi Y, Arslan AD, Clymer J, Alvarez AA, Goldman S, Cheng SY, Nakano I, Horbinski C, Davuluri RV, James CD, Platanias LC.

Mol Cancer Res. 2016 Oct;14(10):984-993. Epub 2016 Jun 30.

38.

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.

Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B.

Cancer Cell. 2016 Apr 11;29(4):563-573. doi: 10.1016/j.ccell.2016.03.012.

39.

Viral Interactions with PDZ Domain-Containing Proteins-An Oncogenic Trait?

James CD, Roberts S.

Pathogens. 2016 Jan 18;5(1). pii: E8. doi: 10.3390/pathogens5010008. Review.

40.

Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):395. doi: 10.1007/s11060-015-2024-6. No abstract available.

PMID:
26782702
41.

Energy Scaling Advantages of Resistive Memory Crossbar Based Computation and Its Application to Sparse Coding.

Agarwal S, Quach TT, Parekh O, Hsia AH, DeBenedictis EP, James CD, Marinella MJ, Aimone JB.

Front Neurosci. 2016 Jan 6;9:484. doi: 10.3389/fnins.2015.00484. eCollection 2015.

42.

Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.

Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK.

Cancer Res. 2015 Dec 15;75(24):5355-66. doi: 10.1158/0008-5472.CAN-14-3689. Epub 2015 Nov 16.

43.

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):385-93. doi: 10.1007/s11060-015-1939-2. Epub 2015 Sep 18. Erratum in: J Neurooncol. 2016 Feb;126(3):395.

44.

EAG2 potassium channel with evolutionarily conserved function as a brain tumor target.

Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, Yang H, Wang TA, Stehbens SJ, Younger S, Barshow S, Zhu S, Cooper MK, Peacock J, Ramaswamy V, Garzia L, Wu X, Remke M, Forester CM, Kim CC, Weiss WA, James CD, Shuman MA, Bader GD, Mueller S, Taylor MD, Jan YN, Jan LY.

Nat Neurosci. 2015 Sep;18(9):1236-46. doi: 10.1038/nn.4088. Epub 2015 Aug 10.

45.

EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.

Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T.

Oncotarget. 2015 Sep 8;6(26):21993-2005.

46.

Induction frequency affects cortico-striatal synaptic plasticity with implications for frequency filtering.

Baca M, Schiess AR, Jelenik D, James CD, Donald Partridge L.

Brain Res. 2015 Jul 30;1615:80-88. doi: 10.1016/j.brainres.2015.04.031. Epub 2015 Apr 23.

PMID:
25912436
47.

The human papillomavirus type 16 L1 protein directly interacts with E2 and enhances E2-dependent replication and transcription activation.

Siddiqa A, Léon KC, James CD, Bhatti MF, Roberts S, Parish JL.

J Gen Virol. 2015 Aug;96(8):2274-85. doi: 10.1099/vir.0.000162. Epub 2015 Apr 24.

48.

miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.

Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, Zhang H, James CD, Sznajder JI, Chin L, Giljohann DA, Kessler JA, Peter ME, Mirkin CA, Stegh AH.

Genes Dev. 2015 Apr 1;29(7):732-45. doi: 10.1101/gad.257394.114.

49.

Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.

Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR.

PLoS One. 2015 Feb 6;10(2):e0117781. doi: 10.1371/journal.pone.0117781. eCollection 2015.

50.

Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma.

Li N, Maly DJ, Chanthery YH, Sirkis DW, Nakamura JL, Berger MS, James CD, Shokat KM, Weiss WA, Persson AI.

Mol Cancer Ther. 2015 Feb;14(2):419-28. doi: 10.1158/1535-7163.MCT-14-0526. Epub 2014 Dec 18.

Supplemental Content

Loading ...
Support Center